Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1053)	7/13/1999 9:05:00 AM
From: LLCF	Respond to of 1073

Neuroinvestment on the Bloomberg... the "A" portfolio beat a flat index by producing a 11.5% return at it's mid-year update. Bloomberg "snips"; "It continues to be those companies with drugs in or near commercialization that will outperform, and some will appreciate in spectacular fashion. In the next 3 months corporate partnerships will validate the market potential of drugs from PARS and IPIC. IPIC will also benefit form the impending resolution of its legal concers, and before the end of the year will file its application to market the first practically useful treatment for stroke. With some companies likely to show a doubling or tripling of their value over the next six months, we continue to see 1999 as the best year for neuropharm companies since 1995." DAK